Sirolimus-eluting Coronary Stent is cost effective vs. bypass surgery
WASHINGTON, D.C. OCTOBER 20, 2005 – An independent analysis of a clinical trial comparing the cost-effectiveness of the CYPHER® Sirolimus-eluting Coronary Stent vs. bypass surgery suggests that treatment with the CYPHER® Stent offers a potential cost-savings over bypass surgery. The findings from the Arterial Revascularization Therapy Study (ARTS) I and II were presented today at the annual Transcatheter Cardiovascular Therapeutics (TCT 2005) Conference.
Treatment of multi-vessel coronary artery disease with the CYPHER® Stent was found to be substantially more cost-effective than bypass surgery both during initial hospitalization and at the one-year follow-up.
According to David J. Cohen, M.D., M.Sc., Associate Director of Interventional Cardiology at Beth Israel Deaconess Medical Center in Boston, and Director of Cardiovascular Outcomes Research, Harvard Clinical Research Institute, who presented the results, "These findings provide additional evidence on the benefit of drug-eluting stents in treating complex patient cases that would have been directed to surgery," Dr. Cohen said. "Furthermore, the analysis shows that the economic benefit of the CYPHER® Stent technology is as significant as the clinical benefit we see in these challenging patient cases."
To account for baseline differences, both costs and event rates from ARTS-II were adjusted to reflect the number of a patient's diseased vessels and whether or not the patient had diabetes. Savings related to the avoidance of death, heart attack, revascularization and stroke were examined.
Initial hospitalization costs, accounting for physician fees, room and ancillary charges, and repeat procedures, were $7,700 less (29 percent) for CYPHER® Stent than for CABG, at $26,419 and $34,119 respectively.
Total one-year costs, when adjusted for patient differences in extent of coronary artery disease and diabetes, were $6,487 less (21 percent) for CYPHER® Stent than for CABG, at $30,388 and $36,875 respectively.
ARTS II is a single arm, randomized multi-center trial of 607 patients in 19 countries. The study sample was drawn from the ARTS-I randomized trial (1997-1998) and the ARTS-II registry (2003). Study criteria included patients with multivessel disease who required treatment of at least two major coronary arteries and who had stenoses that would be receptive to stenting.
Source: Eurekalert & others
Published on PsychCentral.com. All rights reserved.